Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Reports
Email Alerts
Contact Us
Investors & News
Latest News
October 20,2021
Stealth BioTherapeutics Receives Refusal to File Letter from the FDA
October 7,2021
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
October 20, 2021
Form 6-K : Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16
HTML
October 20, 2021
Form 424B3 : Prospectus filed pursuant to Rule 424(b)(3)
HTML
Reports
Latest Presentations
August 18, 2021
Investor Presentation August 2021
August 05, 2021
Second Quarter 2021 Financial Results Earnings Call
Presentations
Events
September 30, 2021
Cantor Global Healthcare Conference Fireside Chat
Webcast
September 13, 2021
H.C. Wainwright 23rd Annual Global Investment Conference Presentation
Webcast
Financial Calendar
Media Relations
Amelia Stetler, 617-762-2562
media@stealthbt.com
Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com
